



(12) Translation of
European patent specification

(11) NO/EP 3272343 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/137 (2006.01)
A61P 25/22 (2006.01)
A61P 25/24 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.06.15
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.02.12
(86)	European Application Nr.	17185830.1
(86)	European Filing Date	2012.04.27
(87)	The European Application's Publication Date	2018.01.24
(30)	Priority	2011.04.29, EP, 11003508
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2701693, 2012.04.27
(73)	Proprietor	Grünenthal GmbH, Zieglerstrasse 6, 52078 Aachen, Tyskland
(72)	Inventor	STEIGERWALD, Ilona, Lintertstraße 52, 52078 Aachen, Tyskland JAHNEL, Ulrich, Am alten Flugplatz 68, 42855 Remscheid, Tyskland TZSCHENTKE, Thomas, Schulstraße 15, 52080 Aachen, Tyskland
(74)	Agent or Attorney	Orsnes Patent ApS, Forskerparken 10, 5230 ODENSE, Danmark

(54)	Title	TAPENTADOL FOR PREVENTING AND TREATING DEPRESSION AND ANXIETY
(56)	References Cited:	KUPERWASSER B ET AL: "337 EVALUATION OF LONG-TERM TREATMENT WITH TAPENTADOL EXTENDED RELEASE AND OXYCODONE CONTROLLED RELEASE IN PATIENTS WITH CHRONIC LOW BACK OR OSTEOARTHRITIS PAIN: RESULTS FROM PATIENT AND PHYSICIAN GLOBAL ASSESSMENTS AND THE EUROQOL 5 DIMENSION QUESTIONNAIRE", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 17, 1 September 2009 (2009-09-01), page S179, XP026582221, ISSN: 1063-4584, DOI: DOI:10.1016/S1063-4584(09)60359-9 [retrieved on 2009-09-01] KUPERWASSER B ET AL: "337 HEALTH STATUS OF PATIENTS WHO RECEIVED TAPENTADOL PROLONGED RELEASE DURING AN OPEN-LABEL EXTENSION STUDY", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 18, 1 October 2010 (2010-10-01), page S149, XP027316893, ISSN: 1063-4584 [retrieved on 2010-09-29] Ingvar Bjelland ET AL: "The validity of the Hospital Anxiety and Depression Scale. An updated literature review", Journal of psychosomatic research, 1 February 2002 (2002-02-01), pages 69- 77, XP55421094, England DOI: 10.1016/S0022-3999(01)00296-3 Retrieved from the Internet:

URL:<https://www.sciencedirect.com/science/article/pii/S0022399901002963>

ILONA STEIGERWALD ET AL: "Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study", JOURNAL OF PAIN RESEARCH, 1 June 2012 (2012-06-01), page 121, XP055564495, DOI: 10.2147/JPR.S30540

LANGE R ET AL: "333 SHORT FORM-36 (SF-36) AND EUROQOL-5 DIMENSION (EQ-5D) RESULTS FROM RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDIES OF TAPENTADOL PROLONGED RELEASE (PR) IN PATIENTS WITH MODERATE TO SEVERE CHRONIC NOCICEPTIVE AND NEUROPATHIC PAIN", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 18, 1 October 2010 (2010-10-01), pages S147-S148, XP027316889, ISSN: 1063-4584 [retrieved on 2010-09-29]

SCHWARTZ SHERWYN ET AL: "Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.", CURRENT MEDICAL RESEARCH AND OPINION JAN 2011 LNKD- PUBMED:21162697, vol. 27, no. 1, January 2011 (2011-01), pages 151-162, XP009150479, ISSN: 1473-4877

AFILALO MARC ET AL: "Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Study", CLINICAL DRUG INVESTIGATION, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 30, no. 8, 1 August 2010 (2010-08-01), pages 489-505, XP009148168, ISSN: 1173-2563, DOI: DOI:10.2165/11533440-000000000-00000

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Tapentadol for anvendelse i behandling av depresjon og/eller angst hos et individ som lider av kronisk giktsmerte, under forutsetning av at tapentadol ikke administreres i kombinasjon med et antiepileptikum.
2. Tapentadol for anvendelse ifølge krav 1, under forutsetning av at tapentadol ikke administreres i kombinasjon med en AMPA-reseptorantagonist.
3. Tapentadol for anvendelse ifølge krav 1 eller 2, hvori tapentadol administreres som eneste farmakologisk aktive ingrediens.
4. Tapentadol for anvendelse ifølge hvilke som helst av de foregående kravene, hvori tapentadol administreres oralt.
5. Tapentadol for anvendelse ifølge hvilke som helst av de foregående kravene, hvori tapentadol administreres
 - én gang daglig eller to ganger daglig, og/eller
 - i en daglig dose innenfor området fra 25 til 600 mg.
6. Tapentadol for anvendelse ifølge hvilke som helst av de foregående kravene, hvori smerten er moderat til sterk.